help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hozawa, S.
Right arrow Articles by Yamakido, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hozawa, S.
Right arrow Articles by Yamakido, M.

Am. J. Respir. Crit. Care Med., Vol 152, No. 4, Oct 1995, 1198-1202.

Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma

S Hozawa, Y Haruta, S Ishioka and M Yamakido
2nd Department of Internal Medicine, Hiroshima University School of Medicine, Japan.

The involvement of platelet-activating factor (PAF) in bronchial hyperresponsiveness (BHR) in bronchial asthma has been controversial. To determine whether PAF is involved in BHR in humans, we carried out a randomized, double-blind, placebo-controlled, two-phase cross-over study on the effects of Y-24180, a potent, specific, orally active PAF receptor antagonist, on BHR to methacholine in patients with asthma. The subjects were 13 patients with extrinsic stable asthma. The provocative concentration of methacholine producing a 20% fall in FEV1 (PC20-FEV1) was measured as an index of BHR. Y-24180 (20 mg twice a day) or a placebo was orally administered for 2 wk, respectively. At the time of cross-over from the first treatment regimen to the second regimen, administration of the test drug was suspended for 2 wk. The methacholine challenge test was performed four times, before and after the first treatment period and before and after the second treatment period. Compared with the placebo, Y-24180 significantly (p = 0.005) improved the PC20-FEV1 value without carryover effect and period effect by analysis of variance. These results suggest that PAF is an important mediator involved in the BHR of bronchial asthma in humans.


This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
S. H. Cho, C. H. Ryu, and C. K. Oh
Plasminogen Activator Inhibitor-1 in the Pathogenesis of Asthma
Experimental Biology and Medicine, February 1, 2004; 229(2): 138 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. NAGASE, S. ISHII, H. SHINDOU, Y. OUCHI, and T. SHIMIZU
Airway Hyperresponsiveness in Transgenic Mice Overexpressing Platelet Activating Factor Receptor Is Mediated by an Atropine-Sensitive Pathway
Am. J. Respir. Crit. Care Med., January 15, 2002; 165(2): 200 - 205.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. R. HENIG, M. L. AITKEN, M. C. LIU, A. S. YU, and W. R. HENDERSON Jr.
Effect of Recombinant Human Platelet-activating Factor-Acetylhydrolase on Allergen-induced Asthmatic Responses
Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 523 - 527.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. FUKUYAMA, H. INOUE, H. AIZAWA, M. OIKE, M. KITAURA, O. YOSHIE, and N. HARA
Effect of Eotaxin and Platelet-activating Factor on Airway Inflammation and Hyperresponsiveness in Guinea Pigs in Vivo
Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1844 - 1849.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
W. R. Henderson Jr., J. Lu, K. M. Poole, G. N. Dietsch, and E. Y. Chi
Recombinant Human Platelet-Activating Factor- Acetylhydrolase Inhibits Airway Inflammation and Hyperreactivity in Mouse Asthma Model
J. Immunol., March 15, 2000; 164(6): 3360 - 3367.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. SATOH, K. ASANO, K. NAOKI, K. FUKUNAGA, M. IWATA, M. KANAZAWA, and K. YAMAGUCHI
Plasma Platelet-activating Factor Acetylhydrolase Deficiency in Japanese Patients with Asthma
Am. J. Respir. Crit. Care Med., March 1, 1999; 159(3): 974 - 979.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
K. R. Bartemes, S. McKinney, G. J. Gleich, and H. Kita
Endogenous Platelet-Activating Factor Is Critically Involved in Effector Functions of Eosinophils Stimulated with IL-5 or IgG
J. Immunol., March 1, 1999; 162(5): 2982 - 2989.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Tamaoki, I. Yamawaki, E. Tagaya, M. Kondo, K. Aoshiba, J. Nakata, and A. Nagai
Effect of azelastine on platelet-activating factor-induced microvascular leakage in rat airways
Am J Physiol Lung Cell Mol Physiol, February 1, 1999; 276(2): L351 - L357.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. J. Barnes, K. F. Chung, and C. P. Page
Inflammatory Mediators of Asthma: An Update
Pharmacol. Rev., December 1, 1998; 50(4): 515 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. NAGASE, S. ISHII, H. KATAYAMA, Y. FUKUCHI, Y. OUCHI, and T. SHIMIZU
Airway Responsiveness in Transgenic Mice Overexpressing Platelet-activating Factor Receptor . Roles of Thromboxanes and Leukotrienes
Am. J. Respir. Crit. Care Med., November 1, 1997; 156(5): 1621 - 1627.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. J. EVANS, P. J. BARNES, M. CLUZEL, and B. J. O'CONNOR
Effects of a Potent Platelet-activating Factor Antagonist, SR27417A, on Allergen-induced Asthmatic Responses
Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 11 - 16.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1995 American Thoracic Society